The word “Ozempic” first entered the language in 2018 when it was approved as a diabetes inhibitor. That same year, in what has to be the world’s biggest ‘off-label’ transference since the heart-disease drug Viagra became a multi-billion-dollar erectile dysfunction drug, Novo Nordisk started selling Ozempic as a weight-loss drug for very obese people.

Then in 2023, Ozempic and its fellow “GLP-1” drugs were shown to prevent strokes and heart attacks.

The next year, it made a claim to reduce kidney disease.

This year, it showed promising results in reducing the effects of Parkinson’s, as well as alcoholism and addiction, and to reduce obesity-related cancers as well.

My physician wife often says that the more unrelated diseases a drug claims to cure, the more it looks like snake oil. In the case of Ozempic, she’d be happy to be wrong. It really does look to be a universal solvent, curing most everything it touches. True, it’s so new that there hasn’t been time to understand its long-term effects. Maybe it will be the next thalidomide whose crippling effects revealed themselves not in its patients, but in their children.

Read on…